New ruthenium(II)-letrozole complexes as anticancer therapeutics.
J Med Chem
; 55(20): 8799-806, 2012 Oct 25.
Article
em En
| MEDLINE
| ID: mdl-22991922
ABSTRACT
Novel ruthenium-letrozole complexes have been prepared, and cell viability of two human cancer cell types (breast and glioblastoma) was determined. Some ruthenium compounds are known for their cytotoxicity to cancer cells, whereas letrozole is an aromatase inhibitor administered after surgery to post-menopausal women with hormonally responsive breast cancer. A significant in vitro activity was established for complex 5·Let against breast cancer MCF-7 cells and significantly lower activity against glioblastoma U251N cells. The activity of 5·Let was even higher than that of 4, a compound analogous to the well-known drug RAPTA-C. Results from the combination of 5·Let (or 4) with 3-methyladenine (3-MA) or with curcumin, respectively, revealed that the resultant cancer cell death likely involves 5·Let-induced autophagy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Rutênio
/
Triazóis
/
Inibidores da Aromatase
/
Complexos de Coordenação
/
Antineoplásicos
/
Nitrilas
Limite:
Female
/
Humans
Idioma:
En
Revista:
J Med Chem
Ano de publicação:
2012
Tipo de documento:
Article